company background image
RMD logo

ResMed NYSE:RMD Stock Report

Last Price

US$180.29

Market Cap

US$26.6b

7D

-0.1%

1Y

-15.7%

Updated

21 Feb, 2024

Data

Company Financials +

RMD Stock Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.

RMD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends4/6

ResMed Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ResMed
Historical stock prices
Current Share PriceUS$180.29
52 Week HighUS$243.52
52 Week LowUS$132.24
Beta0.69
1 Month Change1.96%
3 Month Change18.14%
1 Year Change-15.75%
3 Year Change-10.29%
5 Year Change77.07%
Change since IPO26,733.86%

Recent News & Updates

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Recent updates

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

ResMed: The GARP Story Continues, Technicals Showing Vital Signs

Jan 26

Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

Jan 23
Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Dec 28
We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

Dec 16
Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends

Nov 14

ResMed declares $0.44 dividend

Oct 27

These 4 Measures Indicate That ResMed (NYSE:RMD) Is Using Debt Reasonably Well

Oct 22
These 4 Measures Indicate That ResMed (NYSE:RMD) Is Using Debt Reasonably Well

ResMed raised to Buy at BofA citing Q1 beat

Oct 20

Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

Oct 10
Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

Here's Why We Think ResMed (NYSE:RMD) Is Well Worth Watching

Sep 28
Here's Why We Think ResMed (NYSE:RMD) Is Well Worth Watching

ResMed: Further Downside Is Warranted

Aug 29

Estimating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Aug 23
Estimating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Shareholder Returns

RMDUS Medical EquipmentUS Market
7D-0.1%1.7%-0.5%
1Y-15.7%11.6%22.5%

Return vs Industry: RMD underperformed the US Medical Equipment industry which returned 11.3% over the past year.

Return vs Market: RMD underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is RMD's price volatile compared to industry and market?
RMD volatility
RMD Average Weekly Movement4.0%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: RMD has not had significant price volatility in the past 3 months.

Volatility Over Time: RMD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198910,140Mick Farrellhttps://www.resmed.com

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

ResMed Inc. Fundamentals Summary

How do ResMed's earnings and revenue compare to its market cap?
RMD fundamental statistics
Market capUS$26.58b
Earnings (TTM)US$890.39m
Revenue (TTM)US$4.50b

29.8x

P/E Ratio

5.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RMD income statement (TTM)
RevenueUS$4.50b
Cost of RevenueUS$1.99b
Gross ProfitUS$2.52b
Other ExpensesUS$1.63b
EarningsUS$890.39m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)6.05
Gross Margin55.86%
Net Profit Margin19.77%
Debt/Equity Ratio27.4%

How did RMD perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

30%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.